Search bioRxiv⌕ Search

bioRxiv · 10.1101/2021.10.08.463622

Defining the Characteristics of Type I Interferon Stimulated Genes: Insight from Expression Data and Machine Learning

Abstract

A virus-infected cell triggers a signalling cascade resulting in the secretion of interferons (IFNs), which in turn induce the up-regulation of IFN-stimulated genes (ISGs) that play an important role in the inhibition of the viral infection and the return to cellular homeostasis. Here, we conduct detailed analyses on 7443 features relating to evolutionary conservation, nucleotide composition, gene expression, amino acid composition, and network properties to elucidate factors associated with the stimulation of genes in response to type I IFNs. Our results show that ISGs are less evolutionary conserved than genes that are not significantly stimulated in IFN experiments (non-ISGs). ISGs show significant depletion of GC-content in the coding region of their canonical transcripts, which leads to under-representation in the nucleotide compositions. Differences between ISGs and non-ISGs are also reflected in the properties of their coded amino acid sequence compositions. Network analyses show that ISG products tend to be involved in key paths but are away from hubs or bottlenecks of the human protein-protein interaction (PPI) network. Our analyses also show that interferon-repressed human genes (IRGs), which are down-regulated in the presence of IFNs, can have similar properties to ISGs, thus leading to false positives in ISG predictions. Based on these analyses, we design a machine learning framework integrating the usage of support vector machine (SVM) and feature selection algorithms. The ISG prediction achieves an area under the receiver operating characteristic curve (AUC) of 0.7455 and demonstrates the similarity between ISGs triggered by type I and III IFNs. Our machine learning model predicts a number of genes as potential ISGs that so far have shown no significant differential expression when stimulated with IFN in the cell types and tissue types compiled in the available IFN-related databases. A webserver implementing our method is accessible at http://isgpre.cvr.gla.ac.uk/. Author summaryInterferons (IFNs) are signalling proteins secreted from host cells. IFN-triggered signalling activates the host immune system in response to intra-cellular infection. It results in the stimulation of many genes that have anti-pathogen roles in host defenses. Interferon-stimulated genes (ISGs) have unique properties that make them different from those not significantly up-regulated in response to IFNs (non-ISGs). We find the down-regulated interferon-repressed genes (IRGs) have some shared properties with ISGs. This increases the difficulty of distinguishing ISGs from non-ISGs. The use of machine learning is a sensible strategy to provide high throughput classifications of putative ISGs, for investigation with in vivo or in vitro experiments. Machine learning can also be applied to human genes for which there are insufficient expression levels before and after IFN treatment in various experiments. Additionally, the interferon type has some impact on ISG predictability. We expect that our study will provide new insight into better understanding the inherent characteristics of human genes that are related to response in the presence of IFNs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Chai, H., Hughes, J., Gu, Q., Robertson, D. L.. 2021-10-09. Defining the Characteristics of Type I Interferon Stimulated Genes: Insight from Expression Data and Machine Learning. https://doi.org/10.1101/2021.10.08.463622

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

De novo design of CR2 binder as vaccine scaffold

Efficient B cell activation during vaccine-induced humoral immunity relies on both B cell receptor (BCR) antigen recognition and synergistic signaling from co-receptors. Complement receptor 2 (CR2), the primary BCR co-receptor on B cells, lowers the activation threshold and amplifies downstream kinase signaling by orders of magnitude when engaged by complement fragment C3d decorated antigens. Targeting CR2 therefore represents a rational vaccine enhancement strategy, yet native C3d suffers from low affinity, poor stability, and manufacturing challenges. Here, we report the de novo design of a highly stable, high-affinity CR2 binder using deep learning driving protein design methods. Biophysical characterization, high-resolution cryoEM structural determination, and functional assays in vitro and in vivo confirm that the designed binder matches computational design models and specifically engages CR2 to boost B cell activation. When fused to antigen as a vaccine scaffold, the trimeric CR2 binder elicits robust humoral immune responses comparable to nanoparticle vaccines, while retaining the simplicity of single-chain protein production. Our work establishes a modular CR2 targeting vaccine scaffold platform with broad translational potential for next-generation protein vaccines.

immunology↗

Chronic opioid-associated immune dysregulation among people living with HIV

Objectives: Persistent immune dysregulation contributes to chronic disease among people living with HIV (PWH), even after viral suppression with antiretroviral therapy (ART). Although chronic opioid exposure is associated with adverse clinical outcomes, its impact on immune homeostasis during ART remains incompletely understood. We investigated whether opioid use disorder (OUD) is associated with persistent systemic and cellular immune dysregulation despite ART-mediated reductions in HIV viral load (VL). Methods: Peripheral blood was collected longitudinally from PWH with OUD (PWH/OUD+) and detectable HIV VL during 6 months of optimized ART (months 0, 3, and 6). A reference cohort of PWH without OUD (PWH/OUD-) and suppressed HIV VL provided a single blood sample. Immune profiling included plasma inflammatory biomarkers, multiplex cytokine analyses, spectral flow cytometry, and assessment of monocyte cytokine responses following lipopolysaccharide (LPS) stimulation. Mixed-effects models adjusted for HIV VL and VL-stratified analyses were performed. Results: PWH/OUD+ exhibited persistent immune dysregulation despite reductions in HIV VL. Plasma sCD163, sCD14, fractalkine, and I-TAC remained elevated, whereas TGF-{beta}1 was reduced. OUD was associated with expansion of CD16 monocytes and altered expression of CCR2, CD38, and CD11b. CD4 and CD8 T cells, NK cells, and B cells also exhibited persistent alterations in markers of activation, metabolism, and trafficking. Monocytes from PWH/OUD+ displayed attenuated cytokine responses following LPS stimulation. Conclusions: OUD is associated with persistent systemic and cellular immune dysfunction in PWH despite ART-mediated viral suppression, supporting opioid exposure as an independent contributor to chronic immune dysregulation that may promote inflammation, immune dysfunction, and long-term HIV-associated comorbidities. Keywords: HIV, Opioid-use disorder, innate immunity, cytokine

immunology↗

The mitochondrial RNA extrusion-induced innate immunity is regulated by N6-methyladenosine machinery

Mitochondrial RNA (mtRNA) released into the cytosol functions as a damage associated molecular pattern that activates pattern-recognition receptor (PRR)-mediated inflammation, yet its release mechanisms and cytoplasmic fate remain poorly understood. Here we report that chemical Abt-373-treatment and Vesicular stomatitis virus (VSV) infection induce mtRNA extrusion through Bax/Bak and VDAC1 channels, accompanied by mtDNA release. Extruded mtRNA in A549 cells activates multiple cytosolic PRRs, including RIG-I, MDA5, TLR3/7/8, and PKR, each contributing differentially to the innate immune signaling. Analysis of GEO datasets and methylated RNA immunoprecipitation (MeRIP) assays further reveals that mtRNA carries methyladenosine (m6A) modification. m6A machinery proteins are involved in the cytoplasmic retention time of mtRNA and its interaction with RIG-I, thereby modulating mtRNA-induced innate immunity. Thus, our work establishes in vitro models of mtRNA extrusion, and highlights m6A-dependent modulation as a potential therapeutic target for mtRNA-driven inflammation.

immunology↗